| Literature DB >> 23874065 |
Asahi Hishida1, Rieko Okada, Mariko Naito, Emi Morita, Kenji Wakai, Nobuyuki Hamajima, Satoyo Hosono, Hinako Nanri, Tanvir Chowdhury Turin, Sadao Suzuki, Kazuyo Kuwabara, Haruo Mikami, Sanjeev Budhathoki, Isao Watanabe, Kokichi Arisawa, Michiaki Kubo, Hideo Tanaka.
Abstract
Chronic kidney disease (CKD) is well known as a strong risk factor for both of end-stage renal disease and cardiovascular disease. To clarify the association of polymorphisms in the genes encoding antioxidant enzymes (SOD2, CAT, GPx, TXNRD, SEPP1, SEP15 and SELS) with the risk of CKD in Japanese, we examined this association using the cross-sectional data of Japan Multi-Institutional Collaborative Cohort (J-MICC) Study. The subjects were 3,285 men and women, aged 35-69 years, selected from J-MICC Study participants for whom genotyping were conducted by multiplex polymerase chain reaction-based Invader assay. The prevalence of CKD was determined for CKD stages 3-5 (eGFR <60 ml/min/1.73 m(2)). When those with CAT C-262T C/C were defined as reference, those with CAT C-262T C/T demonstrated the OR for CKD of 0.67 (95% CI 0.43-1.06) with the marginally significant trend for decreased odds ratio with increasing numbers of T allele (p = 0.070). There were no significant associations between the other polymorphisms with CKD risk. The present study found a marginally significant trend of the decreased risk of CKD with increasing numbers of T allele of CAT, which may suggest the possibility of personalized risk estimation of this life-limiting disease in the near future.Entities:
Keywords: antioxidant enzymes; chronic kidney disease; genetic predisposition to disease; single nucleotide polymorphisms
Year: 2013 PMID: 23874065 PMCID: PMC3705159 DOI: 10.3164/jcbn.13-17
Source DB: PubMed Journal: J Clin Biochem Nutr ISSN: 0912-0009 Impact factor: 3.114
Comparison of characteristics between subjects with and without CKD (n = 3,285)
| CKD (+) ( | CKD (–) ( | ||
|---|---|---|---|
| eGFR (ml/min/1.73 m2) | 53.6 ± 6.0 | 78.3 ± 12.5 | <0.001 |
| Age (y) | 60.4 ± 7.2 | 55.9 ± 8.7 | <0.001 |
| Male | 263 (46.3%) | 1,337 (49.2%) | 0.208 |
| Body mass index | 23.5 ± 3.0 | 23.4 ± 3.3 | 0.464 |
| Systolic blood pressure (mmHg) | 130.3 ± 19.8 | 128.2 ± 19.3 | 0.017 |
| Diastolic blood pressure (mmHg) | 79.0 ± 12.4 | 78.7 ± 11.9 | 0.608 |
| Use of anti-hypertensive drugs | 154 (27.1%) | 490 (18.0%) | <0.001 |
| Fasting plasma glucose (mg/dl) | 99.0 ± 22.1 | 100.0 ± 20.9 | 0.351 |
| HbA1c (%) | 5.22 ± 0.69 | 5.22 ± 0.66 | 0.971 |
| Use of glucose-lowering drugs | 32 (5.6%) | 112 (4.1%) | 0.110 |
| Total cholesterol (mg/dl) | 218.5 ± 33.9 | 211.0 ± 33.9 | <0.001 |
| HDL cholesterol (mg/dl) | 61.9 ± 16.0 | 63.3 ± 16.4 | 0.056 |
| Triglyceride (mg/dl) | 107 (77–151) | 104.5 (74–154) | 0.951 |
| Use of lipid-lowering drugs | 73 (12.9%) | 228 (8.4%) | 0.001 |
| Uric acid (mg/dl) | 5.55 ± 1.48 | 5.11 ± 1.33 | <0.001 |
| Cardiovascular diseases | 34 (6.0%) | 80 (2.9%) | 0.001 |
| Cerebrovascular diseases | 31 (5.5%) | 53 (2.0%) | <0.001 |
| Current smokers | 72 (12.7%) | 489 (18.0%) | 0.002 |
| Current drinkers | 298 (52.5%) | 1,522 (56.0%) | 0.126 |
Results are expressed as means ± SD, n (%), or median (interquartile range). CKD = chronic kidney disease. CKD was defined as estimated glomerular filtration rate <60 ml/min/1.73 m2. eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein.
SOD2, CAT, GPx, TXN, SEPP1, SEP15 and SELS polymorphisms and risk of CKD
| Polymorphism | Genotype | CKD (+) ( | CKD (–) ( | aOR (95% CI) | Trend |
|---|---|---|---|---|---|
| 442 (77.8%) | 2,033 (74.8%) | Reference | |||
| 117 (20.6%) | 628 (23.1%) | 0.88 (0.70–1.10) | 0.198 | ||
| 9 (1.6%) | 56 (2.1%) | 0.77 (0.37–1.59) | |||
| 545 (96.0%) | 2,546 (93.7%) | Reference | |||
| 23 (4.0%) | 168 (6.2%) | 0.67 (0.43–1.06) | 0.070 | ||
| 0 (0.0%) | 3 (0.1%) | 0 (–) | |||
| 489 (86.1%) | 2,332 (85.8%) | Reference | |||
| 73 (12.9%) | 364 (13.4%) | 0.94 (0.72–1.24) | 0.951 | ||
| 6 (1.1%) | 21 (0.8%) | 1.37 (0.54–3.49) | |||
| 247 (43.5%) | 1,140 (42.0%) | Reference | |||
| 253 (44.5%) | 1,217 (44.8%) | 0.97 (0.80–1.19) | 0.340 | ||
| 68 (12.0%) | 360 (13.2%) | 0.85 (0.63–1.14) | |||
| 382 (67.3%) | 1,802 (66.3%) | Reference | |||
| 165 (29.0%) | 823 (30.3%) | 0.96 (0.78–1.18) | 0.954 | ||
| 21 (3.7%) | 92 (3.4%) | 1.12 (0.68–1.84) | |||
| 539 (94.9%) | 2,582 (95.0%) | Reference | |||
| 29 (5.1%) | 132 (4.9%) | 1.17 (0.97–1.41) | 0.879 | ||
| 0 (0.0%) | 3 (0.1%) | 1.02 (0.67–1.56) | |||
| 224 (39.4%) | 1,028 (37.8%) | Reference | |||
| 256 (45.1%) | 1,292 (47.6%) | 0.90 (0.73–1.10) | 0.720 | ||
| 88 (15.5%) | 397 (14.6%) | 1.00 (0.76–1.32) | |||
| 242 (42.6%) | 1,138 (41.9%) | Reference | |||
| 245 (43.1%) | 1,253 (46.1%) | 0.90 (0.73–1.10) | 0.745 | ||
| 81 (14.3%) | 326 (12.0%) | 1.00 (0.76–1.32) | |||
| 224 (39.4%) | 1,028 (37.8%) | Reference | |||
| 256 (45.1%) | 1,291 (47.5%) | 0.90 (0.73–1.10) | 0.716 | ||
| 88 (15.5%) | 398 (14.6%) | 1.00 (0.76–1.32) | |||
| 174 (30.6%) | 780 (28.7%) | Reference | |||
| 273 (48.1%) | 1,391 (51.2%) | 0.87 (0.70–1.07) | 0.609 | ||
| 121 (21.3%) | 546 (20.1%) | 0.95 (0.73–1.24) | |||
| 284 (50.0%) | 1,418 (52.2%) | Reference | |||
| 237 (41.7%) | 1,080 (39.7%) | 1.10 (0.90–1.33) | 0.339 | ||
| 47 (8.3%) | 219 (8.1%) | 1.11 (0.78–1.57) | |||
| 520 (91.5%) | 2,493 (91.8%) | Reference | |||
| 47 (8.3%) | 217 (8.0%) | 0.99 (0.70–1.38) | 0.900 | ||
| 1 (0.2%) | 7 (0.3%) | 0.85 (0.10–7.07) |
aOR: adjusted odds ratio (adjusted for age and sex); CKD: chronic kidney disease; SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase; TXNRD, thioredoxin reductase; SEPP, selenoprotein P; SELS, selenoprotein S; SEP15, 15kDa selenoprotein.
Fig. 1Linkage disequilibrium between the 4 SEPP1 polymorphisms.